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Abstract
3,4-methylenedioxymethamphetamine (MDMA; ecstasy) metabolism is known to be stereo-
selective, with preference for S-stereoisomers. Its major metabolic step involves CYP2D6-
catalyzed demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by methyl-
ation and conjugation. Alterations in CYP2D6 genotype and/or phenotype have been associ-
ated with higher toxicity. Therefore, the impact of CYP2D6 function on the plasma
pharmacokinetics of MDMA and its phase I and II metabolites was tested by comparing
extensive metabolizers (EMs), intermediate metabolizers (IMs), and EMs that were pre-
treated with bupropion as a metabolic inhibitor in a controlled MDMA administration study.
Blood plasma samples were collected from 16 healthy participants (13 EMs and three IMs)
up to 24 h after MDMA administration in a double-blind, placebo-controlled, four-period,
cross-over design, with subjects receiving 1 week placebo or bupropion pretreatment fol-
lowed by a single placebo or MDMA (125 mg) dose. Bupropion pretreatment increased the
maximum plasma concentration (Cmax) and area under the plasma concentration-time curve
from 0 to 24 h (AUC24) of R-MDMA (9% and 25%, respectively) and S-MDMA (16% and
38%, respectively). Bupropion reduced the Cmax and AUC24 of the CYP2D6-dependently
formedmetabolite stereoisomers of DHMA 3-sulfate, DHMA 4-sulfate, and 4-hydroxy-3-
methoxymethamphetamine (HMMA sulfate and HMMA glucuronide) by approximately 40%.
The changes that were observed in IMs were generally comparable to bupropion-pretreated
EMs. Although changes in stereoselectivity based on CYP2D6 activity were observed, these
likely have low clinical relevance. Bupropion and hydroxybupropion stereoisomer pharmaco-
kinetics were unaltered by MDMA co-administration. The present data might aid further inter-
pretations of toxicity based on CYP2D6-dependent MDMAmetabolism.
PLOS ONE | DOI:10.1371/journal.pone.0150955 March 11, 2016 1 / 19
a11111
OPEN ACCESS
Citation: Steuer AE, Schmidhauser C, Tingelhoff EH,
Schmid Y, Rickli A, Kraemer T, et al. (2016) Impact of
Cytochrome P450 2D6 Function on the Chiral Blood
Plasma Pharmacokinetics of 3,4-
Methylenedioxymethamphetamine (MDMA) and Its
Phase I and II Metabolites in Humans. PLoS ONE 11
(3): e0150955. doi:10.1371/journal.pone.0150955
Editor: Kenji Hashimoto, Chiba University Center for
Forensic Mental Health, JAPAN
Received: November 19, 2015
Accepted: February 22, 2016
Published: March 11, 2016
Copyright: © 2016 Steuer et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by the Swiss
National Science Foundation SNF (www.snf.ch),
Grant Number 320030_149493, to MEL. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) is an illicit amphetamine derivative
that is used recreationally, usually as a 1:1 mixture of its R- and S-enantiomers. MDMA
enhances feelings of energy, friendliness, euphoria, and empathy [1, 2]. In animals, the S-enan-
tiomer of MDMA or its active metabolite 3,4-methylenedioxyamphetamine (MDA) are more
potent than the R-enantiomers [3–6]. Addionally, S-MDMA has more amphetamine distinc-
tive effects [7] whereas R-MDMA and R-MDA have more hallucinogen-like effects than the S-
enantiomers [8] Acute toxicity (e.g., tachycardia, hypertension, hyperthermia, and hepatotox-
icity) and even fatalities have been associated with the short-term use of MDMA [9, 10]. Neu-
rotoxic effects on serotonergic neurons, presumably via the bioactivation and formation of
glutathione adducts [11–18], are still being investigated and controversially discussed in terms
of species-dependence and dosing [19–21]. Importantly, alterations of cytochrome P450
(CYP)-mediated MDMAmetabolism were shown to influence neurotoxicity [11, 17, 22].
As shown in Fig 1, in humans, MDMA is mainly metabolized by CYP2D6-mediated
O-demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed by catechol-
O-methyltransferase (COMT) O-methylation mainly to 4-hydroxy-3-methoxymethampheta-
mine (HMMA). DHMA is further sulfated mainly by sulfotransferases (SULTs) to DHMA
3-sulfate and DHMA 4-sulfate. HMMA can be further conjugated by UDP-glucuronyltrans-
ferases (UGTs) or SULTs. DHMA 3-sulfate, HMMA sulfate, and HMMA glucuronide were
shown to be the main metabolites in plasma [23] and urine [24], whereas free DHMA and
HMMA were not detectable or only in negligible amounts. A minor pathway includes demeth-
ylation to MDA, mainly by CYP2B6, CYP1A2, and CYP3A4 [25, 26], followed by demethyle-
nation, O-methylation, and conjugation [27–29]. Differences in the metabolism and plasma
pharmacokinetics of the two enantiomers of MDMA were reported in vitro [26, 30–32] and in
vivo [9, 23, 33–36], with higher R-MDMA blood concentrations and preferred elimination
(metabolism and excretion) of S-stereoisomers.
Although CYP2D6 only accounts for approximately 2% of hepatic CYP enzymes, it is
responsible for approximately 19% of drug metabolism [37, 38]. Among the CYP enzymes,
CYP2D6 is the most susceptible to genetic polymorphisms, with more than 100 allelic variants
[37, 38], which can be phenotypically classified into four main groups: poor metabolizer (PM),
intermediate metabolizer (IM), extensive metabolizer (EM), and ultra-rapid metabolizer (UM).
Extensive metabolizers have fully functional enzymes, whereas IMs and PMs exhibit reduced
activity and UMs exhibit increased enzyme activity. Among Caucasians, EMs, IMs, PMs, and
UMs represent approximately 70–80%, 10–17%, 5–10%, and 3–5% of the population, respec-
tively. The participation of CYP2D6 in the metabolism of MDMAmay suggest that individuals
with extensive or even ultrafast metabolism might be at a higher risk for neurotoxic effects,
whereas IMs and/or PMs are more prone to acute MDMA toxicity [17]. However, finding suf-
ficient numbers of UMs and/or PMs for controlled MDMA administration studies is rather dif-
ficult. Co-administering known CYP2D6 inhibitors (e.g., the selective serotonin reuptake
inhibitor [SSRI] paroxetine or fluoxetine) might mimic the IM or PM genotype. Segura et al.
successfully used this approach with paroxetine as a CYP2D6 inhibitor in seven EMs who were
orally administered MDMA [39]. However, the analysis was only performed with racemic
MDMA and free metabolites after conjugate cleavage and did not take into account potential
differences in stereoisomers and the abundance of all metabolites. Bupropion acts as a selective
norepinephrine/dopamine reuptake inhibitor. It was recently used in an interaction study with
MDMA to explore the role of dopamine in the psychotropic effects of MDMA [40]. Bupropion
is commonly used for the treatment of depression and smoking cessation and has been studied
for a number of other diseases (e.g., bipolar disorder and attention-deficit/hyperactivity
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disorder) and weight loss [41, 42]. It is extensively metabolized mainly to hydroxybupropion,
primarily by CYP2B6 as shown in Fig 2, and to a lesser extent to dehydrobupropion (erythro-
hydro- and threohydrobupropion). Plasma pharmacokinetics were shown to differ between
stereoisomers with higher concentrations of R-bupropion and R,R-hydroxybupropion [43],
whereas higher pharmacological potency of S,S-hydroxybupropion was found compared with
both R,R-hydroxybupropion and racemic bupropion. The effects were comparable between
racemic bupropion and each of its enantiomers in vitro, most likely because of its rapid racemi-
zation under physiological conditions. Bupropion and particularly erythrohydro- and threohy-
drobupropion have previously been shown to inhibit CYP2D6 [41, 44, 45].
The aim of the present study was to assess the contribution of CYP2D6 to the chiral
pharmacokinetics of MDMA and its phase I and II metabolites in samples that were collected
during a previous pharmacodynamic interaction study [40]. Thirteen EMs and three IMs
participated in the study, allowing us to explore the effects of genetic differences in CYP2D6
function on MDMAmetabolism. Bupropion was also repeatedly administered prior to
MDMA administration to inhibit CYP2D6 activity, thus allowing exploration of the effect
of pharmacologically inhibiting CYP2D6 on MDMAmetabolism in all of the study
participants.
Fig 1. Main metabolic steps of MDMA.MDMA is mainly metabolized by CYP2D6-mediatedO-demethylenation to 3,4-dihydroxymethamphetamine
(DHMA), followed by catechol-O-methyltransferase (COMT)O-methylation mainly to 4-hydroxy-3-methoxymethamphetamine (HMMA). DHMA is further
sulfated mainly by sulfotransferases (SULTs) to DHMA 3-sulfate (DHMA 3S) and DHMA 4-sulfate (DHMA 4S). HMMA can be further conjugated by UDP-
glucuronyltransferases to HMMA glucuronide (HMMAG) or sulfotransferases to HMMA sulfate (HMMA S). Bold arrows indicate preferences in depicted
metabolic reaction for R- or S-stereoisomer, respectively. Only sulfation of HMMA revealed no enantiomeric preferences.
doi:10.1371/journal.pone.0150955.g001
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Materials and Methods
Chemicals and reagents
The sources of the chemicals and reagents that were used for the MDMA analysis are provided
in detail in a previous study [46]. Methanolic solutions of hydrochlorides of racemic bupropion
(1 mg/ml) and bupropion-d9 (0.1 mg/ml) and acetonitrilic solutions of hydroxybupropion (1
mg/ml) and hydroxybupropion-d6 (0.1 mg/ml) were obtained from Cerilliant and delivered
via Sigma-Aldrich (Buchs, Switzerland).
Clinical study
The study used a double-blind, placebo-controlled, crossover design with four experimental
test sessions (placebo+placebo, bupropion+placebo, placebo+MDMA, and bupropion
+MDMA) in 16 healthy Caucasian subjects (eight men and eight women) with a mean ± SD
age of 24.3 ± 2.2 years and a body mass index of 22.7 ± 2.1 kg/m2 as described in detail in a pre-
vious study [40]. Washout periods between test sessions were at least 10 days. The study was
conducted in accordance with the Declaration of Helsinki and approved by the Ethics Commit-
tee of the Canton of Basel, Switzerland, and the Swiss Agency for Therapeutic Products (Swiss-
medic). The study was registered at ClinicalTrials.gov (NCT01771874). All of the subjects
provided written informed consent and were paid for their participation. Bupropion (Wellbu-
trin XR 150 mg, GlaxoSmithKline, Munchenbuchsee, Switzerland) or placebo was adminis-
tered once daily at a dose of 150 mg for 3 days, followed by administration of 300 mg once
daily for 4 days before the test days. On the test day, the last dose of bupropion or placebo (300
mg) was administered at 8:00 AM, 2 h before MDMA administration (125 mg MDMA
Fig 2. Main metabolic step of bupropion.Chemical structures of bupropion enantiomers and their main
metabolites R,R- and S,S-hydroxybupropion formed through CYP2B6-mediated hydroxylation.
doi:10.1371/journal.pone.0150955.g002
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hydrochloride, Lipomed, Arlesheim, Switzerland), or placebo was administered at 10:00 AM.
Blood samples were collected -2, 0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 h after MDMA or
placebo administration. All of the subjects were genotyped [47] and phenotyped [48] for
CYP2D6 activity. The study included 13 EMs, three IMs, and no PMs (genotyping and pheno-
typing congruent) [40]. Subjects were also genotyped for CYP2B6 (reduced-activity single
nucleotid polymorphism rs3745274 (516G>T, CYP2B66 or CYP2B69) using commercial
TaqMan assay (LuBio Science, Lucerne, Switzerland). There were 9 subjects with the G/G, 6
subjects with the G/T and one subject with the T/T genotype. Subjects with G/T or T/T geno-
type were considered to have a reduced CYP2B6 function.
Chiral analysis of MDMA and metabolites
Blood plasma samples were analyzed non-stereoselectively as reported previously [40] and
reanalyzed for the present report using liquid chromatography-mass spectrometry/mass spec-
trometry after chiral derivatization with Marfey’s reagent as described previously [46]. The
method was fully validated, including selectivity, recovery, matrix effects, bias and imprecision,
stability, and limit of quantification [46].
Chiral analysis of bupropion and hydroxybupropion
Blood plasma samples were analyzed stereoselectively for R- and S-bupropion and their major
metabolites R,R- and S,S-hydroxybupropion according to a previous study [43] with slight
modifications as described in the supporting information (S1 text). The method was fully vali-
dated according to national and international guidelines [49, 50].
Pharmacokinetic analysis
Maximum plasma concentration (Cmax), time to reach Cmax (tmax), area under the plasma con-
centration-time curve from 0 to 24 h (AUC24), AUC from time 0 to infinity (AUC1), and elim-
ination half-life (t1/2) were calculated for all analytes and apparent total clearance (Cl/F) for R-
and S-MDMA using noncompartmental methods (PK solutions 2.0 software, Summit Research
Services, Montrose, CO, USA). The time interval after dosing until detection of the first posi-
tive sample was designated as the time of first detection (tonset). Wilcoxon matched-pairs tests
(95% confidence interval) were used to test for within-subjects differences in pharmacokinetic
parameters between the R and S stereoisomers and between different treatment conditions
(placebo-MDMA vs. bupropion-MDMA, bupropion-placebo vs. bupropion-MDMA). Mann-
Whitney tests (95% confidence interval) were used to test for between-subject differences
between CYP2D6 EMs (n = 13) and CYP2D6 IMs (n = 3). The statistical analyses were per-
formed using Prism 6.00 software (GraphPad Software, La Jolla, CA, USA).
Results
Chiral pharmacokinetics of MDMA and metabolites
Plasma concentration-time profiles for MDMA and metabolites in placebo+MDMA-treated
CYP2D6 EMs and CYP2D6 IMs and bupropion+MDMA-treated EMs are presented in Fig 3.
The pharmacokinetic parameters for all three groups are listed in Table 1. MDMA concentra-
tions were significantly higher in bupropion+MDMA CYP2D6 EMs compared with placebo
+MDMA-treated CYP2D6 EMs (9% and 16% increases in Cmax and 25% and 38% increases in
AUC24 for R- and S-enantiomers, respectively). MDMA concentrations marginally increased
in CYP2D6 IMs compared with the other groups, but the difference was not significant because
of the small number of subjects in the IM group. Bupropion pretreatment reduced the
CYP2D6-Dependent Chiral Pharmacokinetics of MDMA and Metabolites
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Fig 3. Plasma-concentration time profiles of MDMA andmetabolites. Plasma-concentration time profiles
for R- and S-MDMA and R- and S-MDA, R- and S-DHMA 3-sulfate and R- and S-DHMA 4-sulfate, and R-
and S-HMMA sulfate and R- and S-HMMA glucuronide. Black circles and solid lines represent 13 CYP2D6
extensive metabolizers (EM) after placebo-MDMA administration. Triangles and dotted lines represent three
CYP2D6 intermediate metabolizers (IM) after placebo+MDMA administration. Open circles and solid lines
represent 13 CYP2D6 EMs after bupropion+MDMA administration. The data are expressed as mean and
CYP2D6-Dependent Chiral Pharmacokinetics of MDMA and Metabolites
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elimination of MDMA, with a significant prolongation of t1/2 for R-MDMA (31%) and S-
MDMA (26%) and a reduction of Cl/F (-23% and -31%, respectively). The elimination of
MDMA was also marginally reduced in CYP2D6 IMs compared with EMs, but the reduction
was not significant.
For MDA, Cmax (-27% for R-MDA, -24% for S-MDA) and AUC24 values (-26% for R-
MDA, -20% for S-MDA) were reduced by pretreatment with bupropion. Although R-MDA in
CYP2D6 IMs showed the same effect, S-MDA in CYP2D6 IMs was within the same range as in
CYP2D6 EMs. The tmax and t1/2 values for S-MDA were not significantly different. The t1/2 for
R-MDA could not be calculated because of the limited number of data points in the elimination
phase.
The concentrations of all phase II metabolites significantly decreased after bupropion pre-
treatment compared with placebo pretreatment, with lower Cmax and AUC24 values for R-
DHMA 3-sulfate (-68% and -61%), S-DHMA 3-sulfate (-67% and -56%), R-DHMA 4-sulfate
(-54% and -43%), S-DHMA 4-sulfate (-61% and -50%), R-HMMA sulfate (-62% and -62%), S-
HMMA sulfate (-72% and -61%), R-HMMA glucuronide (-77% and -71%), and S-HMMA glu-
curonide (-82% and -74%), respectively. CYP2D6 IMs presented no significant differences
compared with bupropion-treated EMs, although for S-enantiomers sulfates co-administration
of bupropion apparently elevated Cmax while AUC24 remained unaltered. The tmax was reached
significantly later for all phase II metabolites, varying between 40% and 100% for R-stereoiso-
mers and between 45% and 70% for S-stereoisomers, and t1/2 was prolonged up to 200% for R-
stereoisomers and up to 70% for S-stereoisomers after bupropion pretreatment compared with
placebo pretreatment. Similar changes were observed in CYP2D6 IMs compared with EMs,
although to a much lesser extent, especially for R-stereoisomers.
The tonset was comparable between CYP2D6 EMs and IMs for all of the analytes. With
bupropion pretreatment, the first detection of R-HMMA sulfate, S-HMMA sulfate, R-HMMA
glucuronide, and S-HMMA glucuronide was significantly delayed (mean placebo-pretreated
CYP2D6 EMs vs. bupropion-pretreated CYP2D6 EMs: 0.33 h vs. 0.53 h, 0.33 h vs. 0.56 h, 0.41
h vs. 0.73 h, and 0.38 h vs. 0.71 h, respectively).
Generally, alterations in CYP2D6 metabolism that were induced by bupropion pretreatment
influenced both stereoisomers but to slightly different extents. The R/S concentration ratios
over time for MDMA and all metabolites for the different treatment groups are shown in Fig 4.
The MDMA R/S ratio was significantly lower after pretreatment with bupropion (-6% for
Cmax, -9% for AUC24), as was the MDA R/S ratio (-19% for Cmax, -17% for AUC24). The
HMMA sulfate R/S ratio was significantly higher (+21% for Cmax). Although CYP2D6 IMs
appeared to have slightly lower mean R/S ratios than bupropion-pretreated EMs (mainly for
sulfate conjugates), the trend was not significant with regard to Cmax and AUC24 values.
Metabolite/MDMA ratios at each time point for CYP2D6 EMs, IMs, and bupropion-pre-
treated EMs are shown in Fig 5a, exemplified by the R-DHMA 3-sulfate/R-MDMA ratio. Sig-
nificant differences were observed between CYP2D6 EMs and IMs and between placebo-
pretreated EMs and bupropion-pretreated EMs, whereas IMs and bupropion-pretreated EMs
did not differ significantly. The same was observed for all of the other metabolites. Despite sig-
nificant differences between means, the ranges considerably overlapped. Fig 5b shows the
SEM. *p < 0.05, **p < 0.01, ***p < 0.001, significant within-subject difference between placebo+MDMA and
bupropion+MDMA in CYP2D6 EM subjects (Wilcoxon matched-pairs test); +p < 0.05, ++p < 0.01, significant
difference between placebo+MDMA-treated CYP2D6 IMs and bupropion+MDMA-treated CYP2D6 EMs
(Mann-Whitney test).
doi:10.1371/journal.pone.0150955.g003
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Fig 4. R/S ratios of MDMA andmetabolites. R/S concentration ratios for MDMA, MDA, DHMA 3-sulfate, DHMA 4-sulfate, HMMA sulfate, and HMMA
glucuronide over time. Black circles and solid lines represent 13 CYP2D6 extensive metabolizers (EM). Triangles and dotted lines represent three CYP2D6
intermediate metabolizers (IM). Open circles and solid lines represent 13 CYP2D6 EMs after pretreatment with bupropion. The data are expressed as mean
and SEM. *p < 0.05, **p < 0.01, ***p < 0.001, significant within-subject difference between placebo+MDMA and bupropion+MDMA in CYP2D6 EM
subjects (Wilcoxon matched-pairs test); +p < 0.05, ++p < 0.01, significant differences between placebo+MDMA-treated CYP2D6 IMs and bupropion+MDMA-
treated CYP2D6 EMs (Mann-Whitney test).
doi:10.1371/journal.pone.0150955.g004
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changes in metabolite/MDMA ratios over time, with the highest values (mean: 9.9 in placebo-
pretreated EMs, 1.9 in IMs, and 0.4 in bupropion-pretreated EMs) in the first hour after
MDMA administration, decreasing to rather constant values after approximately 2 h (mean:
0.22 in placebo-pretreated EMs, 0.10 in IMs, 0.10 in bupropion-pretreated EMs). The initial
Fig 5. Metabolite ratios. (a) Metabolite ratio of R-DHMA 3-sulfate to R-MDMA in placebo-pretreated CYP2D6 extensive metabolizers (EM), intermediate
metabolizers (IM), and EMs after pretreatment with bupropion. The data represent single measurements of 13 participants (placebo-pretreated EMs and
bupropion-pretreated EMs) or three IMs at different time points after MDMA administration (0.33–24 h). +++p < 0.001, significant difference between placebo
+MDMA-treated CYP2D6 IMs and bupropion+MDMA-treated CYP2D6 EMs (Mann-Whitney test). (b) Metabolite ratio of R-DHMA 3-sulfate to R-MDMA in
CYP2D6 EMs, IMs, and EMs after pretreatment with bupropion over time. Black circles and solid lines represent extensive metabolizers (EM). Triangles and
dotted lines represent intermediate metabolizers (IM). Open circles and solid lines represent EMs after pretreatment with bupropion. The data are expressed
as mean and SEM.
doi:10.1371/journal.pone.0150955.g005
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high ratios were not observed after bupropion-pretreatment. Similar changes in metabolite/
MDMA ratios were observed for all of the other metabolites, with the following mean initial
and constant ratios, respectively: S-DHMA 3-sulfate (33 and 1.1 in placebo-pretreated EMs,
8.8 and 0.42 in IMs, and 1.8 and 0.34 in bupropion-pretreated EMs), R-DHMA 4-sulfate (4.9
and 0.13 in placebo-pretreated EMs, 0.94 and 0.05 in IMs, and 0.89 and 0.05 in bupropion-pre-
treated EMs), S-DHMA 4-sulfate (3.8 and 0.11 in placebo-pretreated EMs, 0.91 and 0.05 in
IMs, and 0.60 and 0.04 in bupropion-pretreated EMs), R-HMMA sulfate (15.8 and 0.54 in pla-
cebo-pretreated EMs, 1.9 and 0.13 in IMs, and 0.31 and 0.13 in bupropion-pretreated EMs), S-
HMMA sulfate (17.7 and 0.86 in placebo-pretreated EMs, 2.3 and 0.28 in IMs, and 0.26 and
0.21 in bupropion-pretreated EMs), R-HMMA glucuronide (1.3 and 0.40 in placebo-pretreated
EMs, 0.05 and 0.05 in IMs, and 0.09 and 0.05 in bupropion-pretreated EMs), and S-HMMA
glucuronide (5.6 and 1.3 in placebo-pretreated EMs, 0.30 and 0.20 in IMs, and 0.10 and 0.20 in
bupropion-pretreated EMs).
The AUC24 metabolite ratios of all CYP2D6-mediated metabolites (R,S-DHMA 3-sulfate, R,
S-DHMA 4-sulfate, R,S-HMMA sulfate, and R,S-HMMA glucuronide) to R/S-MDMA were
significantly different between placebo-pretreated CYP2D6 EMs and IMs and between pla-
cebo-pretreated EMs and bupropion-pretreated EMs but not between IMs and bupropion-pre-
treated EMs (Fig 6). The same result was found for the AUC24 ratio between each single
stereoisomer and MDMA.
Chiral pharmacokinetic analysis of bupropion and hydroxybupropion
Chiral separation was achieved on a chiral AGP column with sufficient separation of each ste-
reoisomer. The respective chromatogram is provided in the Supporting Information (S1 Fig).
Fig 6. Influence of CYP2D6 genotype on MDMAmetabolite formation.Correlations between CYP2D6
genotype (extensive metabolizers [EM], intermediate metabolizers [IM], and bupropion-pretreated EMs) and
AUC24 ratio of the sum of CYP2D6-dependently formed metabolites (DHMA 3-sulfate, DHMA 4-sulfate,
HMMA sulfate, and HMMA glucuronide) to MDMA. The data represent individual participants (EM, n = 13; IM,
n = 3; EMs after bupropion pretreatment, n = 13). *p < 0.05, **p <0.01, ***p < 0.001, significant difference
between EMs and bupropion-pretreated EMs (Wilcoxon matched-pairs test); +p < 0.05, ++p < 0.01, significant
difference between bupropion-pretreated EMs and IMs (Mann-Whitney test).
doi:10.1371/journal.pone.0150955.g006
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The results for recovery, matrix effects, bias, and imprecision are provided in the Supporting
Information (S1 Table). The method was sensitive and selective and showed a linear correla-
tion for each bupropion enantiomer (from 0.5 to 200 ng/ml) and for the two hydroxybupro-
pion stereoisomers (from 2.5 to 1000 ng/ml).
Mean plasma concentration-time profiles for R- and S-bupropion and R,R- and S,S-hydro-
xybupropion after placebo and MDMA co-administration are shown in Fig 7, respectively. The
calculated pharmacokinetic parameters are listed in Table 2. MDMA co-administration did
not significantly alter the concentrations of either R- and S-bupropion or R,R- and S,S-
hydroxybupropion.
Discussion
The co-administration of CYP2D6 inhibitors was used to mimic an IM or PM genotype, which
is a feasible approach to study the influence of CYP2D6 on MDMAmetabolism. Previous stud-
ies used paroxetine as a CYP2D6 inhibitor in seven EMs who were orally administered MDMA
[39, 51]. However, the analysis was only performed with racemic MDMA and free metabolites
after conjugate cleavage. As not only stereoselectivity of MDMA itself, but also of its primary
metabolite DHMA is discussed in terms of (neuro-)toxicity [52, 53] the further metabolic fate
of free DHMA and its resulting stereoselectivities is of interest. Stereoselectivity is not only
obtained from initial formation but rather influenced by follow-up metabolic steps such as
phase II metabolism. Furthermore, recent studies discussed DHMA to play a role in acute car-
diovascular effects observed after MDMA consumption [54]. It was shown that the initial
CYP2D6 metabolite DHMA is not present in human plasma in its free form but rather as its
sulfate conjugates [23, 55], thus making meaningful interpretations of the impact of CYP2D6
difficult because at least one additional metabolic step occurs. Such an analysis after conjugate
cleavage will not represent the actual abundance of all metabolites that are present in plasma,
thus complicating correlations with potential neurotoxicity. Furthermore, CYP2D6 inhibition
might result in higher activity of other CYP enzymes with different stereoselectivity, leading to
Fig 7. Chiral plasma-concentration time profiles for bupropion and hydroxybupropion. Plasma-concentration time profiles for R- and S-bupropion (A)
and R,R- and S,S-hydroxybupropion (B) after co-administration of placebo (black) or MDMA (white). Circles represent R- and R,R-stereoisomers. Triangles
represent S- and S,S-stereoisomers. The data are expressed as mean and SEM (n = 16 participants). Differences between placebo and MDMA were not
statistically significant.
doi:10.1371/journal.pone.0150955.g007
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differences in R- and S-MDMA and consequently different pharmacodynamic effects and
acute toxicity [1, 2, 9, 33, 56]. Therefore, the present study sought to elucidate the effects of
bupropion in mimicking a reduction of CYP2D6 activity in humans and its influence on the
metabolism and pharmacokinetics of MDMA in a stereoselective manner and after direct anal-
ysis of the conjugates. Although from the pharmacological and toxicological point of view no
relevant toxicity is expected from the phase II metabolites as terminal metabolites, their
(stereoselective) formation should majorly influence the concentration and stereoselectivity of
the active metabolite DHMA. Bupropion similarly inhibited CYP2D6 as paroxetine and fluoxe-
tine in vivo, but it is not a substrate of CYP2D6 [44]. The data could then be compared for dif-
ferent genotypes of CYP2D6 (EM and IM).
We found that the pharmacokinetics of MDMA and MDA enantiomers in EMs were com-
parable to those published in other studies [36, 57].
Bupropion increased R- and S-MDMA Cmax and AUC24 values in CYP2D6 EMs resulting
in exposure to MDMA in the same range as previously described for racemic MDMA in one
PM [58] and after CYP2D6 inhibition with paroxetine [39]. The tmax and tonset of both enantio-
mers were unaltered by bupropion, whereas t1/2 was prolonged and plasma clearance was
reduced, suggesting that the metabolic interaction was responsible for differences in pharmaco-
kinetics rather than absorption and/or distribution, which is again consistent with other studies
[39].
R- and S-MDA Cmax and AUC24 values were decreased by the co-administration of bupro-
pion. MDA is mainly formed through CYP2B6, with bupropion as a CYP2B6 substrate [59]
that acts as a competitive inhibitor in this pathway. In CYP2D6 IMs, S-MDA levels were not
significantly different from EMs with regard to either Cmax or AUC24 (Fig 1A). This indicates
the competitive inhibition of CYP2B6 by bupropion. Segura et al. reported an opposite effect
with racemic MDA, in which Cmax and AUC levels increased, thus suggesting accumulation
through the inhibition of subsequent MDA pathways by CYP2D6 [39].
As expected, the co-administration of bupropion and MDMA decreased all metabolites that
are formed CYP2D6-dependently. Although the extent of CYP2D6-inhibition by bupropion
on Cmax and AUC24 values was comparable for R- and S-DHMA, 3-sulfate, R-/S-DHMA 4-sul-
fate, and R-/S-HMMA sulfate, the reduction of S-HMMA glucuronide was significantly greater.
UGTs are enzymes with low affinity for their substrates but high capacity, whereas SULTs have
high affinity for their substrates but are easily saturated. If lower concentrations of HMMA are
Table 2. Pharmacokinetic data of Bupropion (P placebo, M MDMA).
Genotype
CYP2B6
Cmax [ng/ml] tmax [h] AUC0-24h [ng/ml*h-1] AUCtotal [ng/ml*h-1] t1/2 [h]
R/ R,R S/ S,S R/ R,R S/ S,S R/ R,R S/ S,S R/ R,R S/ S,S R/ R,R S/ S,S
Bupropion
P normal 51.2 (6.0) 22.8 (12.3) 5.0 (2.1) 5.0 (1.4) 807 (387) 346 (172) 942 (444) 390 (186) 8.4 (1.8) 7.3 (1.6)
P reduced 68.0 (15.6) 28.6 (3.8) 5.8 (2.5) 5.2 (0.6) 1099 (112) 442 (52.6) 1334 (253) 518 (110) 8.9 (2.9) 7.8 (2.8)
M normal 53.5 (19.4) 21.9 (6.7) 5.2 (2.6) 6.2 (2.4) 822 (237) 344 (75.1) 969 (284) 395 (109) 8.5 (3.3) 7.5 (2.7)
M reduced 68.7 (23.6) 31.4 (17.0) 5.6 (2.3) 4.7 (1.3) 1139 (551) 469 (290) 1313 (669) 533 (339) 7.5 (1.7) 6.8 (1.8)
HO-Bupropion
P normal 542 (145) 26.7 (2.6) 12.3 (5.2) 8.4 (1.7) 13778 (4205) 567 (81.7) n.d. n.d. n.d. n.d.
P reduced 358 (53.3) 18.6 (6.2) 16.9 (7.6) 9.6 (3.3) 9082 (1685) 417 (131) n.d. n.d. n.d. n.d.
M normal 479 (180) 29.4 (13.6) 13.0 (7.2) 7.8 (2.7) 11692 (3122) 521 (187) n.d. n.d. n.d. n.d.
M reduced 452 (180) 29.6 (10.0) 11.7 (4.6) 8.5 (1.4) 10527 (5561) 626 (212) n.d. n.d. n.d. n.d.
doi:10.1371/journal.pone.0150955.t002
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present as a consequence of a decrease in the CYP2D6-dependent formation of DHMA and
consequently HMMA, then the higher affinity of SULT should be more relevant than the
higher capacity of UGTs. Furthermore, UGT inhibition by bupropion might occur [60].
Although no significant differences in Cmax and AUC24 were found between the bupropion-
pretreated CYP2D6 EMs and placebo-pretreated IMs, the S-enantiomer Cmax of sulfate metab-
olites appeared to be lower after bupropion pretreatment in EMs compared with IMs who were
pretreated with placebo. This effect was not observed for HMMA glucuronide. Notably, the
present study only included three IMs. The statistical power, therefore, was rather low, and
true differences might have gone undetected. The tmax of all of the conjugates and tonset for R-
and S-HMMA sulfate and R- and S-HMMA glucuronide were reached significantly later with
bupropion compared with placebo pretreatment, which could be congruent with lower first-
pass metabolism. Additionally, t1/2 was substantially prolonged after bupropion pretreatment
compared with placebo pretreatment, but it was not significantly different between CYP2D6
IMs and EMs. This suggests that other than CYP2D6-mediated interactions might be involved.
Other CYP enzymes might compensate for the decrease in CYP2D6 activity, and different
R- and S- stereoisomer concentrations and thus pharmacological effects might occur due to dif-
ferent potencies of enantiomers[3–6, 52, 53]. For MDMA, significant reductions of R/S ratios
were observed between placebo-pretreated CYP2D6 EMs and bupropion-pretreated EMs but
not between placebo-pretreated CYP2D6 IMs and bupropion-pretreated EMs over 24 h (Fig
4). CYP2D6 preferentially demethylenates S-MDMA, and the inhibitory effect should be more
dominant on that enantiomer, resulting in higher concentrations of the pharmacologically
more active S-MDMA through a reduction of metabolism. The inhibition of CYP2D6 is likely
to result in the loss of metabolic enantioselectivity because other enzymes do not provide com-
parable stereoselectivity as CYP2D6 [26]. However, the observed mean overall effect on
MDMA R/S ratios was less than 10%. MDA showed the same effect, likely because of inhibition
of its metabolism by CYP2D6, which is identical to MDMA. Importantly, MDMA is a
CYP2D6 inhibitor [61], and only one high dose of MDMA was administered, similar to a pre-
vious study [39]. Phase II metabolites represent secondary or even tertiary metabolites that
involve further enzymes. Generally, t1/2 values for R-enantiomers were higher than for S-ste-
reoisomers [23]. After pretreatment with bupropion, the prolongation of t1/2 for R-conjugates
was even higher than for S-enantiomers.
High interindividual variations in plasma concentrations of MDMA and its metabolites
have been reported [23]. The questions how CYP2D6 genotypes or CYP2D6 inhibition alter
concentrations of MDMA [61–63] is of interest in clinical and forensic toxicology. Different
approaches were considered in the present study to address this question. For R/S ratios, only
slight differences between CYP2D6 EMs, IMs, and bupropion-pretreated EMs were observed.
In contrast, significant differences were found for metabolite ratios of CYP2D6-dependetly
formed metabolites to MDMA between groups (Fig 5a, exemplified by the R-DHMA 3-sulfate/
R-MDMA ratio). However, large variations depending on the time post MDMA dose (Fig 5b)
were observed limiting the value of these ratios as useful estimation of CYP2D6 function with-
out knowledge of last MDMA intake in forensic cases. For all conjugates, initial high values
were observed in CYP2D6 EMs, which can be explained by rapidly occurring first-pass metab-
olism. This effect was nearly completely lost in CYP2D6 IMs and after co-administration of the
CYP2D6 inhibitor bupropion, which is consistent with lower first-pass metabolism. Often-
times, correlations between genotypes and phenotypes are based on AUC values or AUC ratios
between metabolites and/or parent compounds. However, in these studies, multiple blood sam-
ples and full pharmacokinetic analysis are necessary. Nevertheless, AUC24 ratios between
MDMA conjugates and MDMA correlated well with CYP2D6 genotype and bupropion-inhib-
ited phenotype (Fig 6).
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Bupropion and its main metabolite hydroxybupropion were analyzed stereoselectively in
the present study to determine the effect of MDMA on bupropion`s complex and stereoselec-
tive metabolism and possible correlations with CYP2D6 inhibition. The minor dehydrometa-
bolite was previously determined in a pharmacodynamics study [40] and thus not included in
the present study. The t1/2 of hydroxybupropion diastereomers could not be determined
because of slow elimination and the limited blood sampling time of only 24 h. Plasma concen-
tration-time profiles were comparable to those in previous studies after a single bupropion
dose [43]. No stereoisomer of bupropion or hydroxybupropion was significantly different
between the bupropion-placebo and bupropion-MDMA groups (Fig 7), indicating that the
CYP2D6 inhibitor MDMA had no influence on bupropion metabolism. This was expected
because bupropion is primarily hydroxylated by CYP2B6 [59]. Although MDMA is also par-
tially cleared by CYP2B6 to MDA, this only represents a minor pathway and is somewhat in
contrast to a previous racemic analysis of the same samples, showing increases in both bupro-
pion and hydroxybupropion through MDMA. However, the observed effect could not be fully
explained [40] and was not reproducible in the chiral reanalysis.
No correlation was found between R- or S-bupropion concentrations and the CYP2D6-de-
pendently formed MDMAmetabolites. Previous studies suggested that bupropion’s metabo-
lites (mainly dehydrobupropion) rather than bupropion itself act as CYP2D6 inhibitors [45].
However, comparisons of R,R-hydroxybupropion, S,S-hydroxybupropion, and dehydrobupro-
pion did not show such a relationship.
Conclusion
The CYP2D6 inhibitor bupropion altered the chiral pharmacokinetics of MDMA. Although
interactions other than the metabolic inhibition of CYP2D6 seem to occur, generally good
agreement was found between the effects of genetically impaired CYP2D6 function (EMs vs.
IMs) and the effects of pharmacological CYP2D6 inhibition (placebo vs. bupropion-pretreated
EMs) on the metabolism of MDMA. CYP2D6 function modulated exposure to MDMA R- and
S-enantiomers, but the clinical implications of this pharmacokinetic interaction remain to be
determined. The present pharmacokinetic data might aid in further interpretations of toxicity
and neurotoxicity based on CYP2D6-dependent MDMAmetabolism and resulting stereoselec-
tive concentrations.
Supporting Information
S1 Fig. Chiral LC-MS/MS analysis of bupropion and hydroxybupropion.MRM chromato-
gram of the chiral analysis of bupropion and hydroxybupropion on a Chiral AGP column.
Depicted are the quantifier MRM chromatograms of R/S-bupropion and R,R-/S,S-hydroxybu-
propion of a QC med sample.
(TIF)
S2 Fig. Consort flow chart. Flow diagram of the progress through the phases of the random-
ized clinical trial including enrolment, intervention allocation, follow-up, and data analysis.
(PPT)
S1 Table. Validation data. Validation data for chiral bupropion analysis, RE: recovery; CV:
coefficient of variation; ME: matrix effect; IS: internal standard; RSDR: intraday precision;
RSDT: interday precision; QC: quality control.
(DOCX)
S1 Text. Chiral analysis of bupropion and hydroxybupropion.
(DOCX)
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